CN105085499A - Crystal separation method for nebivolol hydrochloride intermediate mixture - Google Patents
Crystal separation method for nebivolol hydrochloride intermediate mixture Download PDFInfo
- Publication number
- CN105085499A CN105085499A CN201510481001.7A CN201510481001A CN105085499A CN 105085499 A CN105085499 A CN 105085499A CN 201510481001 A CN201510481001 A CN 201510481001A CN 105085499 A CN105085499 A CN 105085499A
- Authority
- CN
- China
- Prior art keywords
- intermediate mixture
- crystallization
- nebivolol hydrochloride
- mixed solvent
- separation method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- JWEXHQAEWHKGCW-BIISKSHESA-N (R,S,S,S)-nebivolol hydrochloride Chemical compound Cl.C1CC2=CC(F)=CC=C2O[C@H]1[C@@H](O)CNC[C@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 JWEXHQAEWHKGCW-BIISKSHESA-N 0.000 title claims abstract description 39
- 229940068174 nebivolol hydrochloride Drugs 0.000 title claims abstract description 39
- 238000000926 separation method Methods 0.000 title claims abstract description 20
- 239000013078 crystal Substances 0.000 title description 5
- 239000007787 solid Substances 0.000 claims abstract description 76
- 238000002425 crystallisation Methods 0.000 claims abstract description 47
- 230000008025 crystallization Effects 0.000 claims abstract description 47
- 239000012046 mixed solvent Substances 0.000 claims abstract description 46
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 43
- 239000012452 mother liquor Substances 0.000 claims abstract description 39
- 238000001914 filtration Methods 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 23
- 150000001335 aliphatic alkanes Chemical class 0.000 claims abstract description 22
- 239000002904 solvent Substances 0.000 claims abstract description 19
- 239000012141 concentrate Substances 0.000 claims abstract description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 34
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 claims description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 150000001298 alcohols Chemical class 0.000 claims description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 7
- 238000004321 preservation Methods 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 238000009776 industrial production Methods 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 description 24
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 16
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 15
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 10
- 238000001704 evaporation Methods 0.000 description 10
- 230000008020 evaporation Effects 0.000 description 10
- 238000001035 drying Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 2
- 229940124629 β-receptor antagonist Drugs 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- ZQTGOALRHGXOLE-UHFFFAOYSA-N Cc1ccc(CC(CC2)C3OC3)c2c1 Chemical compound Cc1ccc(CC(CC2)C3OC3)c2c1 ZQTGOALRHGXOLE-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B57/00—Separation of optically-active compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了盐酸奈必洛尔中间体混合物的结晶分离方法,包括以下步骤:步骤1、向盐酸奈必洛尔中间体混合物中加入醇类溶剂或醇类与烷烃的混合溶剂,常温溶解成澄清溶液,然后降温结晶,过滤后得到SS/RR型固体;步骤2、将步骤1结晶过滤后的母液浓缩至干,再加入醇类溶剂或醇类与烷烃的混合溶剂,升温溶解成澄清溶液,然后降温结晶,过滤后得到RS/SR型固体。本发明采用结晶分离中间体混合物中的SS/RR型和RS/SR型非对映异构体,操作简单,制备周期较短,同时减少了溶剂的消耗,降低了生产成本和溶剂的后处理成本,有利于实现工业化生产,分离得到的产品的单程收率可达到35~70%。The invention discloses a method for crystallization and separation of a nebivolol hydrochloride intermediate mixture, comprising the following steps: step 1, adding an alcohol solvent or a mixed solvent of alcohol and alkane to the nebivolol hydrochloride intermediate mixture, and dissolving at room temperature into Clarify the solution, then lower the temperature to crystallize, and obtain SS/RR solid after filtration; step 2, concentrate the mother liquor after crystallization and filtration in step 1 to dryness, then add alcohol solvent or a mixed solvent of alcohol and alkanes, and heat up to dissolve into a clear solution , and then cooled to crystallize, and filtered to obtain a RS/SR solid. The present invention uses crystallization to separate SS/RR type and RS/SR type diastereoisomers in the intermediate mixture, has simple operation, short preparation cycle, reduces solvent consumption, reduces production cost and solvent post-treatment low cost, it is beneficial to realize industrial production, and the single-pass yield of the separated product can reach 35-70%.
Description
技术领域 technical field
本发明涉及一种混合物的结晶分离方法,具体涉及盐酸奈必洛尔中间体RS/SR型和SS/RR型混合物的结晶分离方法。 The invention relates to a method for crystallization and separation of a mixture, in particular to a method for crystallization and separation of a mixture of nebivolol hydrochloride intermediate RS/SR type and SS/RR type.
背景技术 Background technique
盐酸奈必洛尔作为第三代β受体拮抗剂,与其他β受体拮抗剂不同,具有更高的选择性,其不会引起支气管平滑肌和血管平滑肌收缩,适应于轻度到中度高血压病人的治疗,同时还可以用于心绞痛和充血性心力衰竭的治疗。 As a third-generation β-receptor antagonist, nebivolol hydrochloride is different from other β-receptor antagonists and has higher selectivity. It does not cause contraction of bronchial smooth muscle and vascular smooth muscle, and is suitable for mild to moderate high The treatment of blood pressure patients can also be used for the treatment of angina pectoris and congestive heart failure.
式I Formula I
式II Formula II
RS/SR(式I)和SS/RR(式II)是合成盐酸奈必洛尔的两个重要的中间体,是一对非对映异构体。目前,式I和式II主要利用柱层析方法进行分离,但该方法存在以下几个问题:1、生产效率较低,生产劳动量较大;2、所使用的溶剂量大;3、收率较低,生产成本偏高等。目前尚未有相关文献和专利报道式I和式II的其它分离方法。 RS/SR (formula I) and SS/RR (formula II) are two important intermediates for the synthesis of nebivolol hydrochloride, which are a pair of diastereoisomers. At present, formula I and formula II are mainly separated by column chromatography, but this method has the following problems: 1, the production efficiency is low, and the production labor is large; 2, the amount of solvent used is large; 3, the yield The rate is low and the production cost is high. At present, there are no other separation methods of formula I and formula II reported in relevant literature and patents.
发明内容 Contents of the invention
本发明所要解决的技术问题是提供一种盐酸奈必洛尔中间体混合物的结晶分离方法。 The technical problem to be solved by the present invention is to provide a method for crystallization and separation of the intermediate mixture of nebivolol hydrochloride.
为解决上述技术问题,本发明采用的技术方案是: In order to solve the problems of the technologies described above, the technical solution adopted in the present invention is:
盐酸奈必洛尔中间体混合物的结晶分离方法,包括以下步骤: The crystallization separation method of nebivolol hydrochloride intermediate mixture comprises the following steps:
步骤1:向盐酸奈必洛尔中间体混合物中加入醇类溶剂或醇类与烷烃的混合溶剂,常温溶解成澄清溶液,然后降温至-10~5°C结晶,保温8~20h,过滤后得到式II的SS/RR型固体: Step 1: Add an alcohol solvent or a mixed solvent of alcohol and alkane to the intermediate mixture of nebivolol hydrochloride, dissolve at room temperature to form a clear solution, then cool down to -10~5°C to crystallize, keep warm for 8~20h, and filter A solid of type SS/RR of formula II is obtained:
式II; Formula II;
步骤2:将步骤1结晶过滤后的母液浓缩至干,再加入醇类溶剂或醇类与烷烃的混合溶剂,升温溶解成澄清溶液,然后降温至0~15℃结晶,保温2~20h,过滤后得到式I的RS/SR型固体: Step 2: Concentrate the mother liquor after crystallization and filtration in step 1 to dryness, then add alcohol solvent or a mixed solvent of alcohol and alkanes, heat up and dissolve into a clear solution, then cool down to 0~15°C to crystallize, keep warm for 2~20h, and filter After obtaining the RS/SR type solid of formula I:
式I。 Formula I.
所述步骤1和步骤2的混合溶剂中,醇类与烷烃的体积比为1:15~15:1。 In the mixed solvent of step 1 and step 2, the volume ratio of alcohols to alkanes is 1:15-15:1.
所述步骤1和步骤2的混合溶剂中,醇类与烷烃的体积比为1:5。 In the mixed solvent of step 1 and step 2, the volume ratio of alcohols to alkanes is 1:5.
所述步骤1中醇类溶剂或醇类与烷烃的混合溶剂的体积(ml)与中间体混合物的质量(g)之间的数值比为1:1~5:1。 In the step 1, the numerical ratio between the volume (ml) of the alcohol solvent or the mixed solvent of alcohol and alkanes to the mass (g) of the intermediate mixture is 1:1-5:1.
所述步骤1中醇类溶剂或醇类与烷烃的混合溶剂的体积(ml)与中间体混合物的质量(g)之间的数值比为2:1。 In the step 1, the numerical ratio between the volume (ml) of the alcohol solvent or the mixed solvent of alcohol and alkanes to the mass (g) of the intermediate mixture is 2:1.
所述步骤2中醇类溶剂或醇类与烷烃的混合溶剂的质量为浓缩后母液质量的5%~25%。 The mass of the alcohol solvent or the mixed solvent of alcohol and alkane in the step 2 is 5%-25% of the mass of the concentrated mother liquor.
所述步骤2中醇类溶剂或醇类与烷烃的混合溶剂的质量为浓缩后母液质量的10%~15%。 The mass of the alcohol solvent or the mixed solvent of alcohol and alkane in the step 2 is 10%-15% of the mass of the concentrated mother liquor.
所述醇类为甲醇、乙醇、异丙醇、正丁醇、叔丁醇、叔戊醇中的一种或多种的混合。 The alcohols are one or more of methanol, ethanol, isopropanol, n-butanol, tert-butanol and tert-amyl alcohol.
所述烷烃为C5~C9烷烃或一种及多种混合物。 The alkanes are C 5 -C 9 alkanes or one or more mixtures.
所述步骤1中澄清溶液降温至-5~0℃结晶。 In the step 1, the clear solution is cooled to -5~0°C to crystallize.
所述步骤1中结晶保温时间为12h。 The crystallization holding time in the step 1 is 12h.
所述步骤2中澄清溶液降温至4~10℃结晶。 In the step 2, the clear solution cools down to 4-10° C. to crystallize.
所述步骤2中结晶保温时间为12h。 The crystallization holding time in the step 2 is 12h.
与现有技术相比,本发明的优点是:本发明采用结晶分离中间体混合物中SS/RR型和RS/SR型非对映异构体,操作简单,制备周期较短,同时减少了溶剂的消耗,降低了生产成本和溶剂的后处理成本,有利于实现工业化生产,分离得到的产品的单程收率可达到35~70%。 Compared with the prior art, the present invention has the advantages that: the present invention adopts crystallization to separate SS/RR type and RS/SR type diastereoisomers in the intermediate mixture, the operation is simple, the preparation period is short, and the solvent is reduced simultaneously. consumption, reduces the production cost and solvent post-treatment cost, and is conducive to the realization of industrial production, and the single-pass yield of the separated product can reach 35-70%.
附图说明 Description of drawings
下面结合附图和具体实施方式对本发明作进一步详细描述。图1是实施例1得到的SS/RR型固体放大10x10后的显微镜图; The present invention will be further described in detail below in conjunction with the accompanying drawings and specific embodiments. Fig. 1 is the microscope picture after the SS/RR type solid that embodiment 1 obtains is enlarged 10x10;
图2是实施例1得到的RS/SR型固体放大40x10后的显微镜图; Fig. 2 is the microscope picture after the RS/SR type solid that embodiment 1 obtains is enlarged 40x10;
图3是实例1得到的SS/RR型固体的DSC谱图; Fig. 3 is the DSC spectrogram of the SS/RR type solid that example 1 obtains;
图4是实例1得到的RS/SR型固体的DSC谱图。 Fig. 4 is the DSC spectrogram of the RS/SR type solid that example 1 obtains.
具体实施方式: Detailed ways:
下面结合具体实施例对本发明的技术方案作进一步的说明。 The technical solutions of the present invention will be further described below in conjunction with specific embodiments.
实施例1 Example 1
在250mL四口瓶中依次投入50g盐酸奈必洛尔的中间体混合物、100mL环己烷和20mL正丁醇,常温溶解成澄清溶液,然后降温至-2°C结晶,保温20小时,过滤后得到18.26gSS/RR型固体,产品纯度≥97%;环己烷与正丁醇按照5:1的体积比配制成混合溶剂,将上述结晶过滤后的母液蒸干,补加10%混合溶剂(相对于蒸干后的母液质量),升温溶解成澄清溶液,然后降温至8°C结晶,保温20小时,过滤后得到20.32gRS/SR型固体,产品纯度≥98%。 Put 50g of nebivolol hydrochloride intermediate mixture, 100mL cyclohexane and 20mL n-butanol into a 250mL four-necked bottle successively, dissolve at room temperature to form a clear solution, then cool down to -2°C to crystallize, keep warm for 20 hours, and filter Obtain 18.26gSS/RR type solid, product purity ≥ 97%; Hexanaphthene and n-butanol are formulated into mixed solvent according to the volume ratio of 5:1, the mother liquor after the above-mentioned crystallization filter is evaporated to dryness, add 10% mixed solvent ( Relative to the quality of the mother liquor after evaporation), the temperature was raised to dissolve into a clear solution, then cooled to 8°C to crystallize, kept for 20 hours, and 20.32g of RS/SR solid was obtained after filtration, with a product purity of ≥98%.
该方法中,式I固体和式II固体的单程收率为70%。 In this method, the single-pass yield of the formula I solid and the formula II solid is 70%.
上述实施实例1得到的SS/RR型固体,经过显微镜测定其晶体外观可知,均具有片状晶习,如图1所示;由DSC测试结果可知其熔点为45.3°C,如图3所示;同时,所得到的RS/SR型固体,经过显微镜测定其晶体外观可知,均具有针状晶习,如图2所示;由DSC测试结果可知其熔点为34.5°C,如图4所示。 The SS/RR type solid that above-mentioned implementation example 1 obtains, it can be seen that its crystal appearance is measured through a microscope, and all has flaky crystal habit, as shown in Figure 1; It can be known that its fusing point is 45.3 ℃ by DSC test result, as shown in Figure 3 Simultaneously, obtained RS/SR type solid, through its crystal appearance of microscopic measurement, all have acicular crystal habit, as shown in Figure 2; It can be known that its fusing point is 34.5 ℃ by DSC test result, as shown in Figure 4 .
实施例2 Example 2
在250mL四口瓶中依次投入60g盐酸奈必洛尔的中间体混合物、100mL正庚烷和20mL正丁醇,常温溶解成澄清溶液,然后降温至-2°C结晶,保温20小时,过滤后得到18.57gSS/RR型固体,产品纯度≥95%;环己烷与正丁醇按照5:1的体积比配制成混合溶剂,将上述结晶过滤后的母液蒸干,补加10%混合溶剂(相对于蒸干后的母液质量),升温溶解成澄清溶液,然后降温至8°C结晶,保温20小时,过滤后得到21.92gRS/SR型固体,产品纯度≥98%。 Put 60g of nebivolol hydrochloride intermediate mixture, 100mL of n-heptane and 20mL of n-butanol into a 250mL four-neck bottle successively, dissolve at room temperature to form a clear solution, then cool down to -2°C to crystallize, keep warm for 20 hours, and filter Obtain 18.57gSS/RR type solid, product purity ≥ 95%; Hexanaphthene and n-butanol are formulated into mixed solvent according to the volume ratio of 5:1, the mother liquor after the above-mentioned crystallization filter is evaporated to dryness, add 10% mixed solvent ( Relative to the quality of the mother liquor after evaporation), the temperature was raised to dissolve into a clear solution, then cooled to 8°C to crystallize, kept for 20 hours, and 21.92g of RS/SR solid was obtained after filtration, with a product purity of ≥98%.
该方法中,式I固体和式II固体的单程收率为68%。 In this method, the single-pass yield of the formula I solid and the formula II solid is 68%.
实施例3 Example 3
在250mL四口瓶中依次投入50g盐酸奈必洛尔的中间体混合物、10mL环己烷和150mL正丁醇,常温溶解成澄清溶液,然后降温至-5°C结晶,保温20小时,过滤后得到15.61gSS/RR型固体,产品纯度≥95%;环己烷与正丁醇按照1:15的体积比配制成混合溶剂,将上述结晶过滤后的母液旋干,补加15%混合溶剂(相对于旋干后的母液质量),升温溶解成澄清溶液,然后降温至5°C结晶,保温20小时,过滤后得到22.51gRS/SR型固体,产品纯度≥97%。 Put 50g of nebivolol hydrochloride intermediate mixture, 10mL cyclohexane and 150mL n-butanol into a 250mL four-neck bottle successively, dissolve at room temperature to form a clear solution, then cool down to -5°C to crystallize, keep warm for 20 hours, and filter Obtain 15.61gSS/RR type solid, product purity ≥ 95%; Hexanaphthene and n-butanol are formulated into mixed solvent according to the volume ratio of 1:15, the mother liquor after the above-mentioned crystallization filter is spin-dried, add 15% mixed solvent ( Relative to the quality of the mother liquor after spin-drying), the temperature was raised to dissolve into a clear solution, and then the temperature was lowered to 5°C to crystallize, and the temperature was kept for 20 hours. After filtration, 22.51g of RS/SR solid was obtained, and the product purity was greater than or equal to 97%.
该方法中,式I固体和式II固体的单程收率为70%。 In this method, the single-pass yield of the formula I solid and the formula II solid is 70%.
实施例4 Example 4
在500mL四口瓶中依次投入80g盐酸奈必洛尔的中间体混合物、150mL环己烷和10mL正丁醇,常温溶解成澄清溶液,然后降温至5°C结晶,保温8小时,过滤后得到30.86gSS/RR型固体,产品纯度≥95%;环己烷与正丁醇按照15:1的体积比配制成混合溶剂,将上述结晶过滤后的母液旋干,补加25%混合溶剂(相对于旋干后的母液质量),升温溶解成澄清溶液,然后降温至5°C结晶,保温2小时,过滤后得到28.85gRS/SR型固体,产品纯度≥97%。 80g of nebivolol hydrochloride intermediate mixture, 150mL of cyclohexane and 10mL of n-butanol were successively put into a 500mL four-neck bottle, dissolved at room temperature to form a clear solution, then cooled to 5°C for crystallization, kept for 8 hours, and filtered to obtain 30.86gSS/RR type solid, product purity ≥ 95%; cyclohexane and n-butanol are formulated into a mixed solvent according to the volume ratio of 15:1, the mother liquor after the above-mentioned crystallization and filtration is spin-dried, and an additional 25% mixed solvent (relatively The quality of the mother liquor after spin-drying), heated up to dissolve into a clear solution, then cooled to 5°C to crystallize, kept warm for 2 hours, and obtained 28.85g RS/SR type solid after filtration, product purity ≥ 97%.
该方法中,式I固体和式II固体的单程收率为70%。 In this method, the single-pass yield of the formula I solid and the formula II solid is 70%.
实施例5 Example 5
在250mL四口瓶中依次投入30g盐酸奈必洛尔的中间体混合物、125mL环己烷和25mL正丁醇,常温溶解成澄清溶液,然后降温至-10°C结晶,保温8小时,过滤后得到10.57gSS/RR型固体,产品纯度≥93%;环己烷与正丁醇按照5:1的体积比配制成混合溶剂,将上述结晶过滤后的母液旋干,补加5%混合溶剂(相对于旋干后的母液质量),升温溶解成澄清溶液,然后降温至10°C结晶,保温2小时,过滤后得到10.41gRS/SR型固体,产品纯度≥97%。 Put 30g of nebivolol hydrochloride intermediate mixture, 125mL cyclohexane and 25mL n-butanol into a 250mL four-necked bottle successively, dissolve at room temperature to form a clear solution, then cool down to -10°C to crystallize, keep warm for 8 hours, and filter Obtain 10.57gSS/RR type solid, product purity ≥ 93%; Hexanaphthene and n-butanol are formulated into mixed solvent according to the volume ratio of 5:1, the mother liquor after the above-mentioned crystallization filter is spin-dried, add 5% mixed solvent ( Relative to the quality of the mother liquor after spin-drying), the temperature was raised to dissolve into a clear solution, and then the temperature was lowered to 10°C to crystallize, kept for 2 hours, and 10.41g of RS/SR solid was obtained after filtration, with a product purity of ≥97%.
该方法中,式I固体和式II固体的单程收率为69%。 In this method, the single-pass yield of the formula I solid and the formula II solid is 69%.
实施例6 Example 6
在500mL四口瓶中依次投入120g盐酸奈必洛尔的中间体混合物、120mL环己烷和20mL正丁醇,常温溶解成澄清溶液,然后降温至-10°C结晶,保温12小时,过滤后得到45.78gSS/RR型固体,产品纯度≥93%;环己烷与正丁醇按照6:1的体积比配制成混合溶剂,将上述结晶过滤后的母液旋干,补加10%混合溶剂(相对于旋干后的母液质量),升温溶解成澄清溶液,然后降温至4°C结晶,保温12小时,过滤后得到50.05gRS/SR型固体,产品纯度≥97%。 Put 120g of nebivolol hydrochloride intermediate mixture, 120mL of cyclohexane and 20mL of n-butanol into a 500mL four-necked bottle successively, dissolve at room temperature to form a clear solution, then cool down to -10°C to crystallize, keep warm for 12 hours, and filter Obtain 45.78gSS/RR type solid, product purity ≥ 93%; Hexanaphthene and n-butanol are formulated into mixed solvent according to the volume ratio of 6:1, the mother liquor after the above-mentioned crystallization filter is spin-dried, add 10% mixed solvent ( Relative to the quality of the mother liquor after spin-drying), the temperature was raised to dissolve into a clear solution, and then cooled to 4°C to crystallize, kept for 12 hours, and 50.05g of RS/SR solid was obtained after filtration, and the product purity was ≥97%.
该方法中,式I固体和式II固体的单程收率为70%。 In this method, the single-pass yield of the formula I solid and the formula II solid is 70%.
实施例7 Example 7
在250mL四口瓶中依次投入60g盐酸奈必洛尔的中间体混合物、120mL环己烷和20mL正丁醇,常温溶解成澄清溶液,然后降温至0°C结晶,保温20小时,过滤后得到25.56gSS/RR型固体,产品纯度≥95%;环己烷与正丁醇按照6:1的体积比配制成混合溶剂,将上述结晶过滤后的母液旋干,补加10%混合溶剂(相对于旋干后的母液质量),升温溶解成澄清溶液,然后降温至15°C结晶,保温20小时,过滤后得到21.18gRS/SR型固体,产品纯度≥97%。 60g of nebivolol hydrochloride intermediate mixture, 120mL of cyclohexane and 20mL of n-butanol were successively put into a 250mL four-necked bottle, dissolved at room temperature to form a clear solution, then cooled to 0°C to crystallize, kept for 20 hours, and filtered to obtain 25.56g SS/RR type solid, product purity ≥ 95%; cyclohexane and n-butanol are formulated into a mixed solvent according to the volume ratio of 6:1, the mother liquor after the above-mentioned crystallization and filtration is spin-dried, and an additional 10% mixed solvent (relatively The mass of the mother liquor after spin-drying) was heated up to dissolve into a clear solution, then cooled to 15°C to crystallize, kept for 20 hours, and 21.18g of RS/SR solid was obtained after filtration, with a product purity of ≥97%.
该方法中,式I固体和式II固体的单程收率为70%。 In this method, the single-pass yield of the formula I solid and the formula II solid is 70%.
实施例8 Example 8
在250mL四口瓶中依次投入50g盐酸奈必洛尔的中间体混合物和100mL叔戊醇,常温溶解成澄清溶液,然后降温至-2°C结晶,保温20小时,过滤后得到15.19gSS/RR型固体,产品纯度≥97%;将上述结晶过滤后的母液蒸干,补加10%叔戊醇(相对于蒸干后的母液质量),升温溶解成澄清溶液,然后降温至4°C结晶,保温20小时,过滤后得到16.92gRS/SR型固体,产品纯度≥98%。 Put 50g of the intermediate mixture of nebivolol hydrochloride and 100mL of tert-amyl alcohol into a 250mL four-neck bottle successively, dissolve at room temperature to form a clear solution, then cool down to -2°C to crystallize, keep warm for 20 hours, and obtain 15.19gSS/RR after filtration Type solid, product purity ≥ 97%; evaporate the mother liquor after the above-mentioned crystallization and filtration to dryness, add 10% tert-amyl alcohol (relative to the quality of the mother liquor after evaporation), heat up and dissolve into a clear solution, and then cool down to 4°C to crystallize , keep warm for 20 hours, and get 16.92g RS/SR type solid after filtration, product purity ≥ 98%.
该方法中,式I固体和式II固体的单程收率为64%。 In this method, the single-pass yield of the formula I solid and the formula II solid is 64%.
实施例9 Example 9
在250mL四口瓶中依次投入55g盐酸奈必洛尔的中间体混合物、100mL正庚烷和20mL叔戊醇,常温溶解成澄清溶液,然后降温至-2°C结晶,保温20小时,过滤后得到16.06gSS/RR型固体,产品纯度≥95%;正庚烷与叔戊醇按照5:1的体积比配制成混合溶剂,将上述结晶过滤后的母液蒸干,补加10%混合溶剂(相对于蒸干后的母液质量),升温溶解成澄清溶液,然后降温至8°C结晶,保温20小时,过滤后得到18.39gRS/SR型固体,产品纯度≥98%。 55g of nebivolol hydrochloride intermediate mixture, 100mL of n-heptane and 20mL of tert-amyl alcohol were successively put into a 250mL four-necked bottle, dissolved at room temperature to form a clear solution, then cooled to -2°C to crystallize, kept for 20 hours, and filtered Obtain 16.06gSS/RR type solid, product purity ≥ 95%; N-heptane and tert-amyl alcohol are formulated into mixed solvent according to the volume ratio of 5:1, the mother liquor after the above-mentioned crystallization filter is evaporated to dryness, add 10% mixed solvent ( Relative to the quality of the mother liquor after evaporation), the temperature was raised to dissolve into a clear solution, then cooled to 8°C to crystallize, kept for 20 hours, and 18.39g of RS/SR solid was obtained after filtration, with a product purity of ≥98%.
该方法中,SS/RR型固体和RS/SR型固体的单程收率为63%。 In this method, the single-pass yield of SS/RR type solid and RS/SR type solid is 63%.
实施例10 Example 10
在250mL四口瓶中依次投入50g盐酸奈必洛尔的中间体混合物、50mL甲醇和50mL叔丁醇,常温溶解成澄清溶液,然后降温至-3°C结晶,保温20小时,过滤后得到20.12gSS/RR型固体,产品纯度≥90%;甲醇与叔丁醇按照1:1的体积比配制成混合溶剂,将上述结晶过滤后的母液蒸干,补加5%混合溶剂(相对于蒸干后的母液质量),升温溶解成澄清溶液,然后降温至10°C结晶,保温20小时,过滤后得到19.31gRS/SR型固体,产品纯度≥90%。 Drop into the intermediate mixture of 50g nebivolol hydrochloride, 50mL methanol and 50mL tert-butanol successively in 250mL four-necked bottle, dissolve into clear solution at room temperature, then cool down to -3°C to crystallize, keep warm for 20 hours, obtain 20.12 after filtration gSS/RR type solid, product purity ≥ 90%; methanol and tert-butanol are formulated into a mixed solvent according to a volume ratio of 1:1, the mother liquor after the above-mentioned crystallization and filtration is evaporated to dryness, and 5% mixed solvent is added (relative to evaporation to dryness) The quality of mother liquor after heating), the temperature rises and dissolves into a clear solution, then cools down to 10°C to crystallize, keeps warm for 20 hours, obtains 19.31g RS/SR type solid after filtration, and the product purity is ≥ 90%.
该方法中,SS/RR型固体和RS/SR型固体的单程收率为42%。 In this method, the single-pass yield of SS/RR type solid and RS/SR type solid is 42%.
实施例11 Example 11
在250mL四口瓶中依次投入50g盐酸奈必洛尔的中间体混合物、50mL乙醇和50mL叔丁醇,常温溶解成澄清溶液,然后降温至-4°C结晶,保温20小时,过滤后得到16.88gSS/RR型固体,产品纯度≥95%;乙醇与叔丁醇按照1:1的体积比配制成混合溶剂,将上述结晶过滤后的母液蒸干,补加8%混合溶剂(相对于蒸干后的母液质量),升温溶解成澄清溶液,然后降温至8°C结晶,保温20小时,过滤后得到14.65gRS/SR型固体,产品纯度≥98%。 In a 250mL four-necked bottle, drop into the intermediate mixture of 50g nebivolol hydrochloride, 50mL ethanol and 50mL tert-butanol successively, dissolve into a clear solution at room temperature, then cool down to -4°C to crystallize, keep warm for 20 hours, and obtain 16.88 gSS/RR type solid, product purity ≥ 95%; ethanol and tert-butanol are formulated into a mixed solvent according to a volume ratio of 1:1, the mother liquor after the above-mentioned crystallization and filtration is evaporated to dryness, and an additional 8% mixed solvent is added (relative to evaporation to dryness) The quality of the mother liquor after), the temperature rises and dissolves into a clear solution, then cools down to 8°C to crystallize, keeps warm for 20 hours, and obtains 14.65g RS/SR type solid after filtration, and the product purity is ≥98%.
该方法中,SS/RR型固体和RS/SR型固体的单程收率为55%。 In this method, the single-pass yield of SS/RR type solid and RS/SR type solid is 55%.
实施例12 Example 12
在250mL四口瓶中依次投入50g盐酸奈必洛尔的中间体混合物、100mL异丙醇,常温溶解成澄清溶液,然后降温至-2°C结晶,保温20小时,过滤后得到16.38gSS/RR型固体,产品纯度≥90%;将上述结晶过滤后的母液蒸干,补加5%异丙醇(相对于蒸干后的母液质量),升温溶解成澄清溶液,然后降温至8°C结晶,保温20小时,过滤后得到15.73gRS/SR型固体,产品纯度≥90%。 Put 50g of the intermediate mixture of nebivolol hydrochloride and 100mL of isopropanol into a 250mL four-necked bottle in turn, dissolve at room temperature to form a clear solution, then cool down to -2°C to crystallize, keep warm for 20 hours, and obtain 16.38gSS/RR after filtration Type solid, product purity ≥ 90%; evaporate the mother liquor after the above-mentioned crystallization and filtration, add 5% isopropanol (relative to the quality of the mother liquor after evaporation), heat up and dissolve into a clear solution, and then cool down to 8°C to crystallize , heat preservation for 20 hours, after filtration, 15.73g RS/SR type solid was obtained, and the product purity was ≥90%.
该方法中,SS/RR型固体和RS/SR型固体的单程收率为40%。 In this method, the single-pass yield of SS/RR type solid and RS/SR type solid is 40%.
实施例13 Example 13
在250mL四口瓶中依次投入50g盐酸奈必洛尔的中间体混合物、50mL乙醇和50mL正庚烷,常温溶解成澄清溶液,然后降温至-3°C结晶,保温20小时,过滤后得到13.93gSS/RR型固体,产品纯度≥90%;乙醇与正庚烷按照1:1的体积比配制成混合溶剂,将上述结晶过滤后的母液蒸干,补加3%混合溶剂(相对于蒸干后的母液质量),升温溶解成澄清溶液,然后降温至6°C结晶,保温20小时,过滤后得到12.03gRS/SR型固体,产品纯度≥90%。 In a 250mL four-necked bottle, drop into the intermediate mixture of 50g of nebivolol hydrochloride, 50mL of ethanol and 50mL of n-heptane successively, dissolve into a clear solution at room temperature, then cool down to -3°C to crystallize, keep warm for 20 hours, and obtain 13.93 gSS/RR type solid, product purity ≥ 90%; ethanol and n-heptane are formulated into a mixed solvent according to the volume ratio of 1:1, the mother liquor after the above-mentioned crystallization and filtration is evaporated to dryness, and 3% mixed solvent is added (relative to evaporation to dryness) The quality of the mother liquor after heating), the temperature was raised to dissolve into a clear solution, and then the temperature was lowered to 6°C to crystallize, and the temperature was kept for 20 hours. After filtration, 12.03g of RS/SR type solid was obtained, and the product purity was ≥90%.
该方法中,SS/RR型固体和RS/SR型固体的单程收率为40%。 In this method, the single-pass yield of SS/RR type solid and RS/SR type solid is 40%.
实施例14 Example 14
在250mL四口瓶中依次投入50g盐酸奈必洛尔的中间体混合物、10mL乙醇和100mL环己烷,常温溶解成澄清溶液,然后降温至-2.5°C结晶,保温20小时,过滤后得到15.48gSS/RR型固体,产品纯度≥85%;乙醇与环己烷按照1:10的体积比配制成混合溶剂,将上述结晶过滤后的母液蒸干,补加5%混合溶剂(相对于蒸干后的母液质量),升温溶解成澄清溶液,然后降温至5°C结晶,保温20小时,过滤后得到15.19gRS/SR型固体,产品纯度≥90%。 50g of nebivolol hydrochloride intermediate mixture, 10mL of ethanol and 100mL of cyclohexane were successively dropped into a 250mL four-necked bottle, dissolved at room temperature into a clear solution, then cooled to -2.5°C for crystallization, kept for 20 hours, and obtained 15.48 gSS/RR type solid, product purity ≥ 85%; ethanol and cyclohexane are formulated into a mixed solvent according to the volume ratio of 1:10, the mother liquor after the above-mentioned crystallization and filtration is evaporated to dryness, and 5% mixed solvent is added (relative to evaporation to dryness) The quality of mother liquor after heating), the temperature rises and dissolves into a clear solution, then cools down to 5°C to crystallize, keeps warm for 20 hours, obtains 15.19g RS/SR type solid after filtration, and the product purity is more than 90%.
该方法中,SS/RR型固体和RS/SR型固体的单程收率为35%。 In this method, the single-pass yield of SS/RR type solid and RS/SR type solid is 35%.
实施例15 Example 15
在250mL四口瓶中依次投入55g盐酸奈必洛尔的中间体混合物、50mL乙醇和50mL石油醚,常温溶解成澄清溶液,然后降温至-2°C结晶,保温20小时,过滤后得到14.32gSS/RR型固体,产品纯度≥90%;乙醇与石油醚按照1:1的体积比配制成混合溶剂,将上述结晶过滤后的母液蒸干,补加2%混合溶剂(相对于蒸干后的母液质量),升温溶解成澄清溶液,然后降温至10°C结晶,保温20小时,过滤后得到12.05gRS/SR型固体,产品纯度≥90%。 Put 55g of nebivolol hydrochloride intermediate mixture, 50mL of ethanol and 50mL of petroleum ether into a 250mL four-necked bottle successively, dissolve into a clear solution at room temperature, then cool down to -2°C to crystallize, keep warm for 20 hours, and obtain 14.32gSS after filtration /RR type solid, product purity ≥ 90%; ethanol and petroleum ether are formulated into a mixed solvent according to the volume ratio of 1:1, the mother liquor after the above-mentioned crystallization and filtration is evaporated to dryness, and 2% mixed solvent is added (relative to the evaporated to dryness) quality of mother liquor), heated up to dissolve into a clear solution, then cooled to 10°C to crystallize, kept warm for 20 hours, and obtained 12.05g RS/SR type solid after filtration, product purity ≥ 90%.
该方法中,SS/RR型固体和RS/SR型固体的单程收率为40%。 In this method, the single-pass yield of SS/RR type solid and RS/SR type solid is 40%.
实施例16 Example 16
在250mL四口瓶中依次投入20g盐酸奈必洛尔的中间体混合物、80mL乙醇,常温溶解成澄清溶液,然后降温至-4°C结晶,保温20小时,过滤后得到7.03gSS/RR型固体,产品纯度≥85%;正庚烷与叔戊醇按照5:1的体积比配制成混合溶剂,将上述结晶过滤后的母液蒸干,补加10%混合溶剂(相对于蒸干后的母液质量),升温溶解成澄清溶液,然后降温至8°C结晶,保温20小时,过滤后得到5.82gRS/SR型固体,产品纯度≥85%。 Put 20g of the intermediate mixture of nebivolol hydrochloride and 80mL of ethanol into a 250mL four-necked bottle successively, dissolve at room temperature to form a clear solution, then cool down to -4°C to crystallize, keep warm for 20 hours, and obtain 7.03g of SS/RR solid after filtration , product purity ≥ 85%; n-heptane and tert-amyl alcohol are formulated into a mixed solvent according to a volume ratio of 5:1, the mother liquor after the above-mentioned crystallization and filtration is evaporated to dryness, and 10% mixed solvent is added (relative to the mother liquor after evaporation to dryness Quality), heated up to dissolve into a clear solution, then cooled to 8°C to crystallize, kept for 20 hours, and filtered to obtain 5.82g RS/SR solid, product purity ≥ 85%.
该方法中,SS/RR型固体和RS/SR型固体的单程收率为35%。 In this method, the single-pass yield of SS/RR type solid and RS/SR type solid is 35%.
上述各实施例并非是限定本发明的实施范围,对于本领域技术人员,只要是不脱离本发明技术原理,只是对本发明做出的非本质性的改变或者修改,均视为本发明权利要求的范围。 The above-mentioned embodiments are not intended to limit the scope of implementation of the present invention. For those skilled in the art, as long as they do not depart from the technical principle of the present invention, only non-essential changes or modifications made to the present invention are considered as claims of the present invention. scope.
Claims (13)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510481001.7A CN105085499B (en) | 2015-08-07 | 2015-08-07 | The Crystallization Separation method of nebivolol hydrochloric acid intermediate mixture |
PCT/CN2016/093201 WO2017024980A1 (en) | 2015-08-07 | 2016-08-04 | Crystallization separation method for nebivolol hydrochloride intermediate mixture |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510481001.7A CN105085499B (en) | 2015-08-07 | 2015-08-07 | The Crystallization Separation method of nebivolol hydrochloric acid intermediate mixture |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105085499A true CN105085499A (en) | 2015-11-25 |
CN105085499B CN105085499B (en) | 2018-09-25 |
Family
ID=54566915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510481001.7A Active CN105085499B (en) | 2015-08-07 | 2015-08-07 | The Crystallization Separation method of nebivolol hydrochloric acid intermediate mixture |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN105085499B (en) |
WO (1) | WO2017024980A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017024980A1 (en) * | 2015-08-07 | 2017-02-16 | 上海现代制药海门有限公司 | Crystallization separation method for nebivolol hydrochloride intermediate mixture |
CN108929284A (en) * | 2017-05-27 | 2018-12-04 | 上海彩迩文生化科技有限公司 | The separation method of morpholine ketone isomers |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0145067A2 (en) * | 1983-12-05 | 1985-06-19 | Janssen Pharmaceutica N.V. | Derivatives of 2,2'-iminobisethanol |
EP0334429A1 (en) * | 1988-03-23 | 1989-09-27 | Janssen Pharmaceutica N.V. | Agents for lowering the blood pressure |
US5759580A (en) * | 1994-02-17 | 1998-06-02 | Janssen Pharmaceutica, N.V. | Compositions containing micronized nebivolol |
WO2004041805A1 (en) * | 2002-11-06 | 2004-05-21 | EGIS Gyógyszergyár Rt. | NEW PROCESS FOR THE PREPARATION OF RACEMIC ([2S[2R*[R[R*]]]] and ([2R[2S*[S[S*]]]]-(±)- α,α' -[imino-bis(methylene)]bis[6-fluorochroman-2-methanol] AND ITS PURE [2S[2R*[R[R*]& |
WO2007083318A1 (en) * | 2006-01-18 | 2007-07-26 | Hetero Drugs Limited | Process for isolation of desired isomers of nebivolol intermediates |
CN101463024A (en) * | 2007-12-21 | 2009-06-24 | 上海现代制药股份有限公司 | Method for preparing RRRS and SSSR type nebivolol intermediate mixture |
CN101541791A (en) * | 2006-11-27 | 2009-09-23 | Zach系统股份公司 | Process for preparing nebivolol |
CN102408402A (en) * | 2011-12-27 | 2012-04-11 | 上海立科药物化学有限公司 | Synthesis method of (R) or (S) -6-fluoro-3, 4-dihydro-2H-1-benzopyran-2-formic acid |
CN102471325A (en) * | 2009-07-23 | 2012-05-23 | Zach系统股份公司 | Process for preparing nebivolol |
CN102858759A (en) * | 2010-02-11 | 2013-01-02 | 马纳里尼国际运转卢森堡股份公司 | Process for the preparation of nebivolol |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1803716B1 (en) * | 2005-12-28 | 2012-07-25 | Acino Pharma AG | A process for preparation of racemic nebivolol |
CN103910704B (en) * | 2013-01-05 | 2016-06-22 | 重庆福安药业(集团)股份有限公司 | A kind of Preparation Method And Their Intermediate compound of nebivolol |
CN105085499B (en) * | 2015-08-07 | 2018-09-25 | 上海现代制药海门有限公司 | The Crystallization Separation method of nebivolol hydrochloric acid intermediate mixture |
-
2015
- 2015-08-07 CN CN201510481001.7A patent/CN105085499B/en active Active
-
2016
- 2016-08-04 WO PCT/CN2016/093201 patent/WO2017024980A1/en active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0145067A2 (en) * | 1983-12-05 | 1985-06-19 | Janssen Pharmaceutica N.V. | Derivatives of 2,2'-iminobisethanol |
EP0334429A1 (en) * | 1988-03-23 | 1989-09-27 | Janssen Pharmaceutica N.V. | Agents for lowering the blood pressure |
US5759580A (en) * | 1994-02-17 | 1998-06-02 | Janssen Pharmaceutica, N.V. | Compositions containing micronized nebivolol |
WO2004041805A1 (en) * | 2002-11-06 | 2004-05-21 | EGIS Gyógyszergyár Rt. | NEW PROCESS FOR THE PREPARATION OF RACEMIC ([2S[2R*[R[R*]]]] and ([2R[2S*[S[S*]]]]-(±)- α,α' -[imino-bis(methylene)]bis[6-fluorochroman-2-methanol] AND ITS PURE [2S[2R*[R[R*]& |
WO2007083318A1 (en) * | 2006-01-18 | 2007-07-26 | Hetero Drugs Limited | Process for isolation of desired isomers of nebivolol intermediates |
CN101541791A (en) * | 2006-11-27 | 2009-09-23 | Zach系统股份公司 | Process for preparing nebivolol |
CN101463024A (en) * | 2007-12-21 | 2009-06-24 | 上海现代制药股份有限公司 | Method for preparing RRRS and SSSR type nebivolol intermediate mixture |
CN102471325A (en) * | 2009-07-23 | 2012-05-23 | Zach系统股份公司 | Process for preparing nebivolol |
CN102858759A (en) * | 2010-02-11 | 2013-01-02 | 马纳里尼国际运转卢森堡股份公司 | Process for the preparation of nebivolol |
CN102408402A (en) * | 2011-12-27 | 2012-04-11 | 上海立科药物化学有限公司 | Synthesis method of (R) or (S) -6-fluoro-3, 4-dihydro-2H-1-benzopyran-2-formic acid |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017024980A1 (en) * | 2015-08-07 | 2017-02-16 | 上海现代制药海门有限公司 | Crystallization separation method for nebivolol hydrochloride intermediate mixture |
CN108929284A (en) * | 2017-05-27 | 2018-12-04 | 上海彩迩文生化科技有限公司 | The separation method of morpholine ketone isomers |
CN108929284B (en) * | 2017-05-27 | 2022-08-02 | 上海彩迩文生化科技有限公司 | Separation method of morpholone isomers |
Also Published As
Publication number | Publication date |
---|---|
CN105085499B (en) | 2018-09-25 |
WO2017024980A1 (en) | 2017-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109180749B (en) | Method for preparing high-purity N-acetylneuraminic acid hydrate by using supersaturation crystallization method | |
CN105085499B (en) | The Crystallization Separation method of nebivolol hydrochloric acid intermediate mixture | |
CN103012472B (en) | Crystal preparation method of creatine phosphate sodium | |
CN104478746B (en) | A kind of preparation method of DL-Lys | |
CN105085395A (en) | Preparation method for bedaquiline | |
CN104086550B (en) | A kind of synthetic method of tetramethyluric acid | |
CN105837658B (en) | A kind of synthetic method of argatroban | |
CN105085396B (en) | For preparing shellfish up to intermediate of quinoline and its preparation method and application | |
CN104619681A (en) | Method for producing (r)-1,1,3-trimethyl-4-aminoindane | |
CN109897009B (en) | Apabetalone hydrate crystal form and preparation method thereof | |
ES2746016T3 (en) | Procedure for the preparation of fingolimod hydrochloride crystals | |
CN101265215A (en) | A kind of preparation method of D-citalopram intermediate S-type diol | |
CN103172696B (en) | A kind of preparation method of perindopril arginine salt of gamma crystal form | |
WO2018045629A1 (en) | Method for preparing voriconazole l-camphorsulphonate and voriconazole | |
CN103755609B (en) | Crystal formation of tartaric acid valnemulin and preparation method thereof | |
CN101570492B (en) | Chemical method for synthesizing ephedrine | |
CN102827237B (en) | One class asiatic acid amino butanetriol salt crystal formation and preparation method thereof | |
WO2015085827A1 (en) | Method for preparing silodosin and intermediate thereof | |
CN115710263A (en) | Crystal form of berberine new salt and preparation method thereof | |
WO2016150337A1 (en) | Ahu377 crystal form, preparation method and use thereof | |
CN107056700A (en) | A kind of Resolution method of tetrahydroisoquinolicompounds compounds racemic modification | |
CN101613349B (en) | The preparation method of S-3-aminoquinine dihydrochloride | |
CN113583017B (en) | Method for selectively extracting and separating artemisinin/arteannuin by using hydrophilic ionic liquid | |
CN113957106B (en) | A method for preparing Avacopan and its intermediates | |
CN105820069A (en) | N-{4-[3-(3-bromo-phenyl)-ureidomethyl]-2,5-dibutoxy-phenyl}-methanesulfonamide new compound and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Dongya Inventor after: Tang Qiyun Inventor after: Tang Hongye Inventor after: Yu Zhenpeng Inventor after: He Kangyong Inventor after: Li Haifeng Inventor after: Zou Lingyan Inventor before: Zhang Dongya Inventor before: Tang Qiyun Inventor before: Tang Hongye Inventor before: Yu Zhenpeng Inventor before: He Kangyong Inventor before: Li Haifeng |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 226100 No.1, Linjiang Avenue, Linjiang Town, Haimen District, Nantong City, Jiangsu Province Patentee after: Jiangsu Weiqida Pharmaceutical Co., Ltd Patentee after: SHANGSHAI SHYNDEC PHARMACEUTICAL Co.,Ltd. Address before: 226100 No.3 Inner 2, Lingdian Industrial Centralized East District, Haimen City, Nantong City, Jiangsu Province Patentee before: SHANGHAI SHYNDEC PHARMACEUTICAL Co.,Ltd. Patentee before: SHANGSHAI SHYNDEC PHARMACEUTICAL Co.,Ltd. |